Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K, Inoue M, Washino S, Shirotake S, Kagawa M, Takeshita H, Miura Y, Hyodo Y, Oyama M, Kawakami S, Miyagawa T, Saito K, Kageyama Y. Izumi K, et al. Among authors: oyama m. Int J Urol. 2023 Sep;30(9):714-721. doi: 10.1111/iju.15128. Epub 2022 Dec 21. Int J Urol. 2023. PMID: 36541136
The predictive value of C-reactive protein for prognosis in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy: a multi-institutional study.
Tanaka N, Kikuchi E, Shirotake S, Kanao K, Matsumoto K, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Ito Y, Kosaka T, Kodaira K, Oyama M, Miyajima A, Momma T, Nakagawa K, Ueno M, Oya M. Tanaka N, et al. Among authors: oyama m. Eur Urol. 2014 Jan;65(1):227-34. doi: 10.1016/j.eururo.2012.11.050. Epub 2012 Dec 1. Eur Urol. 2014. PMID: 23219372
The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Nakajima Y, Oya M. Tanaka N, et al. Among authors: oyama m. Urol Oncol. 2014 Jan;32(1):48.e19-26. doi: 10.1016/j.urolonc.2013.07.003. Epub 2013 Sep 18. Urol Oncol. 2014. PMID: 24055429
Independent predictors for bladder outcomes after treatment of intravesical recurrence following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Hagiwara M, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Hasegawa S, Nakajima Y, Oya M. Tanaka N, et al. Among authors: oyama m. Ann Surg Oncol. 2014 Sep;21(9):3151-8. doi: 10.1245/s10434-014-3657-y. Epub 2014 Mar 29. Ann Surg Oncol. 2014. PMID: 24682698
A multi-institutional validation of the prognostic value of the neutrophil-to-lymphocyte ratio for upper tract urothelial carcinoma treated with radical nephroureterectomy.
Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Miyazaki Y, Kobayashi H, Kaneko G, Hagiwara M, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Hara S, Oyama M, Momma T, Nakajima Y, Jinzaki M, Oya M. Tanaka N, et al. Among authors: oyama m. Ann Surg Oncol. 2014 Nov;21(12):4041-8. doi: 10.1245/s10434-014-3830-3. Epub 2014 Jun 10. Ann Surg Oncol. 2014. PMID: 24912614
Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience.
Shirotake S, Kikuchi E, Tanaka N, Matsumoto K, Miyazaki Y, Kobayashi H, Ide H, Obata J, Hoshino K, Kaneko G, Hagiwara M, Kosaka T, Kanao K, Kodaira K, Hara S, Oyama M, Momma T, Miyajima A, Nakagawa K, Hasegawa S, Nakajima Y, Oya M. Shirotake S, et al. Among authors: oyama m. J Urol. 2015 Apr;193(4):1122-8. doi: 10.1016/j.juro.2014.10.022. Epub 2014 Oct 13. J Urol. 2015. PMID: 25444957
Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy.
Kobayashi H, Kikuchi E, Tanaka N, Shirotake S, Miyazaki Y, Ide H, Obata J, Hoshino K, Matsumoto K, Kaneko G, Hagiwara M, Kosaka T, Oyama M, Nakajima Y, Oya M. Kobayashi H, et al. Among authors: oyama m. Jpn J Clin Oncol. 2016 Jun;46(6):554-559. doi: 10.1093/jjco/hyw028. Epub 2016 Mar 9. Jpn J Clin Oncol. 2016. PMID: 26962241
Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings.
Tanaka N, Mizuno R, Shirotake S, Ito K, Yasumizu Y, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Oya M. Tanaka N, et al. Among authors: oyama m. Urol Oncol. 2016 Jul;34(7):293.e17-25. doi: 10.1016/j.urolonc.2016.02.023. Epub 2016 Apr 1. Urol Oncol. 2016. PMID: 27040380
Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma.
Shirotake S, Yasumizu Y, Ito K, Masunaga A, Ito Y, Miyazaki Y, Hagiwara M, Kanao K, Mikami S, Nakagawa K, Momma T, Masuda T, Asano T, Oyama M, Tanaka N, Mizuno R, Oya M. Shirotake S, et al. Among authors: oyama m. Clin Genitourin Cancer. 2016 Dec;14(6):e575-e583. doi: 10.1016/j.clgc.2016.03.014. Epub 2016 Mar 24. Clin Genitourin Cancer. 2016. PMID: 27102405
728 results